These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8744035)

  • 1. Lipids and progressive renal failure.
    Keane WF; Guijarro C
    Contrib Nephrol; 1996; 118():17-23. PubMed ID: 8744035
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
    Guijarro C; Keane WF
    Miner Electrolyte Metab; 1996; 22(1-3):147-52. PubMed ID: 8676808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipids and progressive renal failure.
    Keane WF
    Wien Klin Wochenschr; 1996; 108(14):420-4. PubMed ID: 8784983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis.
    Kasiske BL; O'Donnell MP; Kim Y; Atluru D; Keane WF
    Kidney Int Suppl; 1994 Feb; 45():S51-3. PubMed ID: 8158898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lipids on glomerular injury and progression of renal disease.
    Keane WF
    Verh K Acad Geneeskd Belg; 1994; 56(2):91-104. PubMed ID: 8048270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipids and the progression of renal disease.
    Keane WF; O'Donnell MP; Kasiske BL; Schmitz PG
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S69-74. PubMed ID: 16989069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mevalonate pathway: importance in mesangial cell biology and glomerular disease.
    O'Donnell MP; Kasiske BL; Kim Y; Atluru D; Keane WF
    Miner Electrolyte Metab; 1993; 19(3):173-9. PubMed ID: 8232104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C1Q nephropathy in children.
    Kersnik Levart T; Kenda RB; Avgustin Cavić M; Ferluga D; Hvala A; Vizjak A
    Pediatr Nephrol; 2005 Dec; 20(12):1756-61. PubMed ID: 16247648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipids and renal disease.
    Trevisan R; Dodesini AR; Lepore G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S145-7. PubMed ID: 16565240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of renal failure and lipids--is there evidence for a link in humans?
    Attman PO
    Nephrol Dial Transplant; 1998 Mar; 13(3):545-7. PubMed ID: 9550623
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatocyte growth factor-stimulating endothelial cell growth and accelerating glomerular capillary repair in experimental progressive glomerulonephritis.
    Mori T; Shimizu A; Masuda Y; Fukuda Y; Yamanaka N
    Nephron Exp Nephrol; 2003; 94(2):e44-54. PubMed ID: 12845230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteinuria and renal insufficiency three years after treatment of gastric lymphoma.
    Markowitz GS; Goldstein CS; D'Agati VD
    Am J Kidney Dis; 1999 Sep; 34(3):588-93. PubMed ID: 10469874
    [No Abstract]   [Full Text] [Related]  

  • 13. Cell cycle regulatory proteins in glomerular disease.
    Shankland SJ
    Kidney Int; 1999 Oct; 56(4):1208-15. PubMed ID: 10610411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of U-937 monocyte adhesion to cultured human mesangial cells by cytokines and vasoactive agents.
    Menè P; Fais S; Cinotti GA; Pugliese F; Luttmann W; Thierauch KH
    Nephrol Dial Transplant; 1995; 10(4):481-9. PubMed ID: 7542754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does extracellular matrix expansion in glomerular disease require mesangial cell proliferation?
    Eng E; Floege J; Young BA; Couser WG; Johnson RJ
    Kidney Int Suppl; 1994 Feb; 45():S45-7. PubMed ID: 8158896
    [No Abstract]   [Full Text] [Related]  

  • 16. [Analysis of transporter function and development to clinical application].
    Toyohara T; Abe T
    Seikagaku; 2011 Apr; 83(4):323-8. PubMed ID: 21626887
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of multicentric Castleman's disease with membranoproliferative glomerulonephritis type 3-like lesion.
    Nagai K; Usui J; Noguchi K; Unai K; Hiwatashi A; Arakawa Y; Togashi A; Morito N; Saito C; Yoh K; Tsuruoka S; Kojima H; Aita K; Nagata M; Yamagata K
    Pathol Int; 2011 Nov; 61(11):686-90. PubMed ID: 22029682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.
    Hohenstein B; Daniel C; Wagner A; Stasch JP; Hugo C
    Am J Physiol Renal Physiol; 2005 Apr; 288(4):F685-93. PubMed ID: 15561976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of IgG Fc fragments prevents glomerular injury in experimental immune complex nephritis.
    Gómez-Guerrero C; Duque N; Casado MT; Pastor C; Blanco J; Mampaso F; Vivanco F; Egido J
    J Immunol; 2000 Feb; 164(4):2092-101. PubMed ID: 10657663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of ankylosing spondylitis associated with hyperthyroidism and mesangial proliferative glomerulonephritis].
    Kohsaka H; Miyasaka N; Satoh K; Yamaoka K; Okuda M; Aoki N
    Ryumachi; 1987 Jun; 27(3):181-7. PubMed ID: 3438779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.